NEVVI Medicare utilization intelligence
or

← back

Provider profile

AHMAD, KALEEM M.D.

Hematology-Oncology · NPI 1629065982 · MARMORA, NJ

1
Groups
41
Codes · 2024
111,822
Disclosed services

AHMAD, KALEEM is a Hematology-Oncology in MARMORA, NJ, a member of 1 medical group, who billed 41 distinct codes to Medicare Part B in 2024.

Groups: REGIONAL CANCER CARE ASSOCIATES LLC (HACKENSACK, NJ)

Year: 2024 · 2023 · 2022 🔒 · 2021 🔒 · 2020 🔒

Provider overview · all codes · CY2024

111,822
disclosed services
41
codes billed to Medicare Part B
Prior year · CY2023 80,345 disclosed services

This provider's disclosed Medicare payments across all codes were in CY2024.

Dollars, place-of-service mix, business mix and national standing are part of the market analytics platform — built, not launched yet. Notify me at launch →

All figures are disclosed (CMS suppresses fewer-than-11-beneficiary rows) Medicare Part B fee-for-service — a subset, never complete totals; volumes are personal to this NPI, not attributed to any group. Standing is a billed-volume position among specialty peers with disclosed billing (national percentile; a provider's true standing can only be higher, never lower), not a statement about care. See Methods & Sources.

Procedures billed to Medicare Part B (2024)

Medicare Part B FFS · CY2024 · as published by CMS
This provider's Medicare volumes — services, beneficiary-episodes, and charges — are part of the market analytics platform — built, not launched yet. Notify me at launch →
CodeDescription Services Beneficiary-episodes Avg charge Avg Medicare payment
J0881 Injection, darbepoetin alfa, 1 microgram (non-esrd use)
Q5110 Injection, filgrastim-aafi, biosimilar, (nivestym), 1 microgram
J0885 Injection, epoetin alfa, (for non-esrd use), 1000 units
J1437 Injection, ferric derisomaltose, 10 mg
J0897 Injection, denosumab, 1 mg
J1453 Injection, fosaprepitant, 1 mg
85025 Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count
Q5119 Injection, rituximab-pvvr, biosimilar, (ruxience), 10 mg
36415 Insertion of needle into vein for collection of blood sample
J1100 Injection, dexamethasone sodium phosphate, 1 mg
J1626 Injection, granisetron hydrochloride, 100 mcg
99214 Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more
96372 Injection of drug or substance under skin or into muscle
96367 Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less
99213 Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more
G2211 Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's
J3490 Unclassified drugs
96413 Administration of chemotherapy into vein, 1 hour or less
96365 Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less
J1200 Injection, diphenhydramine hcl, up to 50 mg
96375 Injection of additional new drug or substance into vein
96366 Infusion into a vein for therapy, prevention, or diagnosis, each additional hour
99211 Office or other outpatient visit for the evaluation and management of established patient that may not require presence of healthcare professional
96415 Administration of chemotherapy into vein, each additional hour
99215 Established patient office or other outpatient visit with high level of medical decision making, if using time, 40 minutes or more
99232 Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes
J3489 Injection, zoledronic acid, 1 mg
J3420 Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg
96401 Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle
85610 Blood test, clotting time
96417 Administration of additional new drug or substance into vein, 1 hour or less
99231 Subsequent hospital care with straightforward or low level of medical decision making, per day, if using time, at least 25 minutes
99195 Drawing of blood for a medical problem
99204 New patient office or other outpatient visit with moderate level of medical decision making, if using time, 45 minutes or more
99222 Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes
99205 New patient office or other outpatient visit with a high level of medical decision making, if using time, 60 minutes or more
93793 Anticoagulant management of patient taking warfarin
99223 Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes
96523 Irrigation of implanted venous access drug delivery device
99212 Established patient office or other outpatient visit with straightforward medical decision making, if using time, 10 minutes or more
99233 Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes

These are this provider's own Medicare Part B fee-for-service volumes (CMS public data). CMS suppresses rows with fewer than 11 beneficiaries, so low-volume codes may be missing entirely — absence is not zero. Beneficiary-episodes count CMS's per-setting beneficiary figures, not unique patients. Average charge and average Medicare payment are weighted by service volume across office and facility settings. Volumes on this page are personal to the NPI and are not attributed to any physician group. See Methods & Sources.